What it is
KLOW is a research-market product: one vial of lyophilised powder containing four peptides that are also sold separately, BPC-157, TB-500, KPV and GHK-Cu. It is GLOW with a fourth peptide added, and the name is built the same way, taking the first letter of each component.
Vendors set their own split of the total vial weight across the four peptides. Compared with the three-peptide GLOW mix, KPV is generally the smallest component by weight, since it is included for a specific anti-inflammatory contribution rather than as a headline ingredient. There is no standard ratio across suppliers, so the composition of any given vial comes down to that seller's label, not a fixed formula.
The four components
BPC-157. A synthetic 15 amino acid peptide based on a fragment of a human gastric-juice protein. It has a large rat and mouse literature on tendon, ligament, muscle and gut healing, and essentially no controlled human data. Full detail: BPC-157.
TB-500. The research-market name for a short, 7 amino acid fragment of thymosin beta-4, a naturally occurring protein involved in cell migration. Most of the substantial published research on thymosin beta-4 used the full 43 amino acid protein rather than this short fragment. Full detail: TB-500.
KPV. A 3 amino acid fragment, lysine-proline-valine, derived from the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH). It is studied mainly in rodent models of colitis and skin inflammation for anti-inflammatory activity that appears separate from alpha-MSH's pigmentation effects. Like the other three, it has no FDA-approved use and is not registered with FDA Philippines.
GHK-Cu. A naturally occurring 3 amino acid peptide that binds copper, involved in collagen and skin-matrix regulation. Human evidence is limited to small topical cosmetic studies; there are no published human injection trials. Full detail: GHK-Cu (injectable).
The rationale for combining all four is that they are thought to act on different parts of tissue repair and inflammation: BPC-157 on blood vessel growth and soft-tissue repair, TB-500 on cell migration, KPV on inflammation, and GHK-Cu on collagen and matrix remodelling. That is a proposed mechanism, not a tested outcome.
What the research found
On the blend. Nothing. No animal or human study has tested BPC-157, TB-500, KPV and GHK-Cu together in one injection. Any claim that mixing the four works better than any one alone, or that they act "synergistically," has not been tested.
On the components. The evidence summarised above belongs to each peptide studied alone, mostly in cells and rodents, and mostly at doses, routes and injection sites different from how the blend is used. Human evidence exists only for topical GHK-Cu; the other three have no controlled human trial data that we could find.
Combining four peptides in one vial also raises questions the published literature does not answer: whether all four remain stable together once reconstituted, and whether copper from GHK-Cu interacts with the other three peptides in solution.
Side effects and safety concerns
There is no controlled human safety data for the blend, or for injected use of BPC-157, TB-500 or KPV individually. All four components appear on the US FDA's list of bulk substances nominated for compounding that may present significant safety risks, each cited for a lack of human safety data and a possible risk of immunogenicity from impurities or aggregation in an injectable product. Those nominations were withdrawn in April 2026, which does not make any of the four an approved or authorised compounding ingredient; several are due for review by FDA's compounding advisory committee.
A four-peptide blend also removes flexibility. Because the ratio is fixed by the vendor, none of the four can be adjusted or stopped on its own, and if a reaction occurs there is no way to tell which peptide, or combination, was responsible.
KLOW vs GLOW vs single peptides
| Product | Contents | Studied as a combination? |
|---|---|---|
| KLOW | BPC-157 + TB-500 + KPV + GHK-Cu | No |
| GLOW | BPC-157 + TB-500 + GHK-Cu | No |
| Single vials | One peptide each | Individual cell and animal data |
Status in the Philippines
None of the four components is registered with FDA Philippines as a medicine, and none is a controlled substance under RA 9165. KLOW is sold by local research-peptide suppliers alongside GLOW and the individual peptides. For reconstitution arithmetic, the reconstitution calculator works on total vial weight; each dose then carries all four peptides in whatever fixed ratio the vendor used.
Local stock KLOW blend 80mg at Primara Labs, delivered in Metro Manila and nationwide. Research use only.
Storage
Keep lyophilised powder refrigerated and away from light. Once reconstituted with bacteriostatic water, store at 2 to 8°C. Blends have no published stability data for the mixture as a whole, so using the vial sooner rather than later is the more cautious approach. During a brownout, a cooler with ice packs beats a warming fridge. See the beginner guide for handling basics.
